Tapimmune Announces Development Of Advanced Immunotherapeutic Vaccine Expression And Delivery System

TapImmune is pleased to announce development of a revolutionary cost effective immunotherapeutic vaccine expression and delivery system. The novel platform is termed TapImmune’s PolyStart™ technology and has been strategically designed to directly enhance the immune system’s ability to stimulate either or BOTH cytotoxic killer and helper T-cell reactive proprietary peptides, known and expected to be…

Details

TapImmune Provides Operational Update including Human Data Supporting Use of TAP Based Cancer Vaccine Company Establishes Laboratory Facilities in Vancouver Canada

ANCOUVER, Canada, 31 July, 2007 – TapImmune Inc., a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, opens new laboratory facilities and provides this update to shareholders. The opening of the new laboratory facility in Vancouver facilitates the transfer of its technology from The University of British Columbia…

Details

TapImmune Inc. Announces Acquisition of Core TAP Technologies and Intellectual Property from The University of British Columbia

New Name to Reflect a New Direction and Independent Operation VANCOUVER, BC – TapImmune Inc. (OTCBB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announced today that it has fulfilled its financial obligation to The University of British Columbia for the proposed acquisition of its key…

Details